Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.65 |
| ▸ | CDK4 | P11802 | 6/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974483 | 0.84 | CDK2 (0.66) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL702195 | 0.83 | CDK2 (0.62) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL7964048 | 0.82 | CDK2 (0.61) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL7978780 | 0.80 | CDK2 (0.62) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL1684673 | 0.78 | CDK2 (0.74) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL699854 | 0.78 | HDAC1 (0.65) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL1684643 | 0.77 | CDK2 (0.86) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL7964815 | 0.77 | CDK2 (0.63) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL1684885 | 0.75 | CDK2 (0.83) | CDK2CDK4CCNE1CDK1HDAC1 | |
| SCHEMBL1684709 | 0.75 | CDK2 (0.83) | CDK2CDK4CCNE1CDK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.